Terms: = Lung cancer AND RAF1, Raf-1, 5894, P04049, ENSG00000132155, c-Raf, CRAF AND Treatment
81 results:
1. Characterization of
Watanabe H; Inoue Y; Karayama M; Yazawa S; Mochizuka Y; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Shinmura K; Inui N; Suda T
JCO Precis Oncol; 2024 Apr; 8():e2300538. PubMed ID: 38662982
[TBL] [Abstract] [Full Text] [Related]
2. Targeting craf kinase in anti-cancer therapy: progress and opportunities.
Wang P; Laster K; Jia X; Dong Z; Liu K
Mol Cancer; 2023 Dec; 22(1):208. PubMed ID: 38111008
[TBL] [Abstract] [Full Text] [Related]
3. CDK10 suppresses metastasis of lung adenocarcinoma through inhibition of the ETS2/c-raf/p-MEK/p-ERK signaling loop.
Zhang X; Zhao Y; Yiminniyaze R; Zhu N; Zhang Y; Wumaier G; Xia J; Dong L; Zhou D; Wang J; Li C; Zhang Y; Li S
Mol Carcinog; 2024 Jan; 63(1):61-74. PubMed ID: 37737453
[TBL] [Abstract] [Full Text] [Related]
4. Gain-of-function mutations in the catalytic domain of
Zhang J; Yang T; Han M; Wang X; Yang W; Guo N; Ren Y; Cui W; Li S; Zhao Y; Zhai X; Jia L; Yang J; Wu C; Wang L
Sci Adv; 2023 Jun; 9(22):eadc9273. PubMed ID: 37256945
[TBL] [Abstract] [Full Text] [Related]
5. Decoding the key compounds and mechanism of Shashen Maidong decoction in the treatment of lung cancer.
Cai J; Chen Y; Wang K; Li Y; Wu J; Yu H; Li Q; Wu Q; Meng W; Wang H; Lu A; Huang M; Wei G; Guan D
BMC Complement Med Ther; 2023 May; 23(1):158. PubMed ID: 37189139
[TBL] [Abstract] [Full Text] [Related]
6. Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in
de Braud F; Dooms C; Heist RS; Lebbe C; Wermke M; Gazzah A; Schadendorf D; Rutkowski P; Wolf J; Ascierto PA; Gil-Bazo I; Kato S; Wolodarski M; McKean M; Muñoz Couselo E; Sebastian M; Santoro A; Cooke V; Manganelli L; Wan K; Gaur A; Kim J; Caponigro G; Couillebault XM; Evans H; Campbell CD; Basu S; Moschetta M; Daud A
J Clin Oncol; 2023 May; 41(14):2651-2660. PubMed ID: 36947734
[TBL] [Abstract] [Full Text] [Related]
7. Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency.
Sun D; Feng F; Teng F; Xie T; Wang J; Xing P; Qian H; Li J
Cell Commun Signal; 2023 Mar; 21(1):48. PubMed ID: 36869329
[TBL] [Abstract] [Full Text] [Related]
8. α4-α5 Helices on Surface of KRAS Can Accommodate Small Compounds That Increase KRAS Signaling While Inducing CRC Cell Death.
Abuasaker B; Garrido E; Vilaplana M; Gómez-Zepeda JD; Brun S; Garcia-Cajide M; Mauvezin C; Jaumot M; Pujol MD; Rubio-Martínez J; Agell N
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614192
[TBL] [Abstract] [Full Text] [Related]
9. Estimated sensitivity profiles of lung cancer specific uncommon BRAF mutants towards experimental and clinically approved kinase inhibitors.
Mullaguri SC; Akula S; Ashireddygari VR; Sahoo PS; Burra VLSP; Silveri R; Mupparapu V; Korikani M; Amanchi NR; Subramanian J; Kancha RK
Toxicol Appl Pharmacol; 2022 Oct; 453():116213. PubMed ID: 36049549
[TBL] [Abstract] [Full Text] [Related]
10. craf dimerization with ARAF regulates KRAS-driven tumor growth.
Venkatanarayan A; Liang J; Yen I; Shanahan F; Haley B; Phu L; Verschueren E; Hinkle TB; Kan D; Segal E; Long JE; Lima T; Liau NPD; Sudhamsu J; Li J; Klijn C; Piskol R; Junttila MR; Shaw AS; Merchant M; Chang MT; Kirkpatrick DS; Malek S
Cell Rep; 2022 Feb; 38(6):110351. PubMed ID: 35139374
[TBL] [Abstract] [Full Text] [Related]
11. Anticancer drug resistance: An update and perspective.
Nussinov R; Tsai CJ; Jang H
Drug Resist Updat; 2021 Dec; 59():100796. PubMed ID: 34953682
[TBL] [Abstract] [Full Text] [Related]
12. MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in
Fanini F; Bandini E; Plousiou M; Carloni S; Wise P; Neviani P; Murtadha M; Foca F; Fabbri F; Vannini I; Fabbri M
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948154
[TBL] [Abstract] [Full Text] [Related]
13. Downregulation of KIF15 inhibits the tumorigenesis of non-small-cell lung cancer via inactivating Raf/MEK/ERK signaling.
Luo Y; Zhang B; Xu L; Li M; Wu J; Zhou Y; Li Y
Histol Histopathol; 2022 Mar; 37(3):269-285. PubMed ID: 34908156
[TBL] [Abstract] [Full Text] [Related]
14. A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab.
Lin J; Wang X; Zhang C; Bu S; Zhao C; Wang H
Front Immunol; 2021; 12():606027. PubMed ID: 34248926
[TBL] [Abstract] [Full Text] [Related]
15. KRAS K104 modification affects the KRAS
Chen CC; Hsu CY; Lin HY; Zeng HQ; Cheng KH; Wu CW; Tsai EM; Hsieh TH
Sci Rep; 2020 Oct; 10(1):17447. PubMed ID: 33060649
[TBL] [Abstract] [Full Text] [Related]
16. Systemic review on B-Raf
Chavda J; Bhatt H
Eur J Med Chem; 2020 Nov; 206():112675. PubMed ID: 32798788
[TBL] [Abstract] [Full Text] [Related]
17. Integration of Liquid Biopsies into Clinical Laboratory Applications via NGS in cancer Diagnostics.
Sonmezler O; Boga I; Bisgin A
Clin Lab; 2020 May; 66(5):. PubMed ID: 32390404
[TBL] [Abstract] [Full Text] [Related]
18. Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.
Desai J; Gan H; Barrow C; Jameson M; Atkinson V; Haydon A; Millward M; Begbie S; Brown M; Markman B; Patterson W; Hill A; Horvath L; Nagrial A; Richardson G; Jackson C; Friedlander M; Parente P; Tran B; Wang L; Chen Y; Tang Z; Huang W; Wu J; Zeng D; Luo L; Solomon B
J Clin Oncol; 2020 Jul; 38(19):2140-2150. PubMed ID: 32182156
[TBL] [Abstract] [Full Text] [Related]
19. Non-canonical raf-1/p70S6K signalling in non-small-cell lung cancer.
Qiu Z; Ye B; Zhao S; Li X; Li L; Mo X; Li W
J Cell Mol Med; 2019 Nov; 23(11):7632-7640. PubMed ID: 31541523
[TBL] [Abstract] [Full Text] [Related]
20. craf mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition.
Noeparast A; Giron P; Noor A; Bahadur Shahi R; De Brakeleer S; Eggermont C; Vandenplas H; Boeckx B; Lambrechts D; De Grève J; Teugels E
Oncogene; 2019 Aug; 38(31):5933-5941. PubMed ID: 31285551
[TBL] [Abstract] [Full Text] [Related]
[Next]
